Summit Therapeutics (NASDAQ:SMMT – Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, October 19th. Analysts expect the company to announce earnings of ($0.2806) per share and revenue of $0.07 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, October 19, 2026 at 8:00 AM ET.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last posted its earnings results on Thursday, July 23rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts expect Summit Therapeutics to post ($1.20) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.
Summit Therapeutics Price Performance
SMMT opened at $14.63 on Friday. Summit Therapeutics has a fifty-two week low of $12.07 and a fifty-two week high of $29.23. The company’s 50 day moving average price is $15.75 and its two-hundred day moving average price is $16.37.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on SMMT. HC Wainwright reiterated a “buy” rating on shares of Summit Therapeutics in a report on Thursday. Barclays boosted their price objective on shares of Summit Therapeutics from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 1st. Sanford C. Bernstein restated a “market perform” rating on shares of Summit Therapeutics in a report on Monday, October 5th. Stifel Nicolaus decreased their price objective on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a report on Friday, July 24th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Summit Therapeutics in a research report on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $28.61.
Check Out Our Latest Research Report on SMMT
Summit Therapeutics Company Profile
Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer.
Summit obtained exclusive rights from Akeso, Inc to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories.
Featured Stories
- Five stocks we like better than Summit Therapeutics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
